Log In
BCIQ
Print this Print this
 

Infimab, biosimilar infliximab (BOW015)

  Manage Alerts
Collapse Summary General Information
Company Epirus Biopharmaceuticals Inc.
DescriptionBiosimilar of infliximab, a chimeric mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentMarketed
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
PartnerChemo Group;
Livzon Pharmaceutical Group Inc.;
Polpharma S.A.;
Sun Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

$305.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today